Marson, A. G. and Sills, G. J. (2015) Valproate. In: Shorvon, S., Perucca, E. and Engel Jr., J. (eds.) The Treatment of Epilepsy. Wiley, pp. 652-666. ISBN 9781118937006 (doi: 10.1002/9781118936979.ch51)

Full text not currently available from Enlighten.


Valproic acid, or valproate, has been in clinical use for the treatment of epilepsy for more than 40 years. In addition to its place in the treatment of epilepsy, valproic acid has gained acceptance in the treatment of conditions that are not included in this chapter, such as affective disorders in psychiatry and the prophylaxis of migraine headaches. Valproic acid differs from all other known antiepileptic drugs (AEDs). It has shown efficacy in an impressively wide range of experimental models, including maximal electroshock‐induced seizures, seizures induced chemically by pentylenetetrazole, bicuculline, glutamic acid, kainic acid, strychnine, ouabain, nicotine and intramuscular penicillin, seizures induced by kindling, and spontaneously occurring seizures in genetic models of generalized epilepsy such as the Genetic Absence Epileptic Rat of Strasbourg (GAERS) rat. It is a valuable antiepileptic drug, particularly in the management of generalized epilepsies, but should be used with caution in females of childbearing potential.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Sills, Dr Graeme
Authors: Marson, A. G., and Sills, G. J.
College/School:College of Medical Veterinary and Life Sciences > School of Life Sciences

University Staff: Request a correction | Enlighten Editors: Update this record